Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/56911—Bacteria
  • G01N33/56927—Chlamydia
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S435/00—Chemistry: molecular biology and microbiology
  • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T436/00—Chemistry: analytical and immunological testing
  • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
  • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
  • Y10T436/143333—Saccharide [e.g., DNA, etc.]
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T436/00—Chemistry: analytical and immunological testing
  • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T436/00—Chemistry: analytical and immunological testing
  • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
  • Y10T436/25125—Digestion or removing interfering materials

Definitions

• This invention relates to assays, and in particular to methods for preparing aqueous samples for use in assays for lipopolysaccharide antigens.
• Lipopolysaccharide antigens are important indicators of the presence of certain pathogenic bacteria, notably Chlamydia. Such assays require the preparation of an aqueous extract from a clinical sample suspected of containing the organisms.
• the sample may, for example, be in the form of a clinical swab taken from a patient.
• An extraction buffer is used to free lipopolysaccharide antigen from organisms that may be present in the sample.
• a typical extraction buffer will contain lysing agents such as detergents.
• the extraction procedure may involve heating of the sample in the extraction buffer, for example to a temperature in the range of 80° to 100° C. After several minutes a sufficient quantity of lipopolysaccharide antigen will have been released from any organisms present to provide basis for an accurate assay.
• EP-A-392865 discusses this problem and recommends that divalent cations should be removed from the system, for example, by chelation with agents such as EDTA.
• EP-A-392865 is particularly concerned with the unwanted presence of divalent cations such as zinc and magnesium.
• Other cationically-charged materials may also be present in the clinical sample. Any of these cationic materials may interfere with the sensitivity of a lipopolysaccharide antigen assay. We believe that this interference arises because the cations bind to a negatively charged region of the lipopolysaccharide molecule and block an important binding site against which antibodies useful in such an assay are raised.
• the invention provides an assay for lipopolysaccharide antigen, conducted in the presence of an anionic polysaccharide in an amount sufficient to reduce interference caused by cations.
• the anionic polysaccharide is a glycosaminoglycan, such as heparin.
• heparin alternatives include heparin sulphate and dermatan sulphate.
• the invention is particularly applicable when the lipopolysaccharide antigen is bacterial, e.g. when the bacteria are Chlamydia.
• the invention also provides an aqueous extraction buffer for solubilizing antigenic material in bacteria and the like, containing an anionic polysaccharide in an amount sufficient to enhance assay sensitivity.
• An important embodiment of the invention is an aqueous extraction buffer for use in solubilizing lipopolysaccharide antigen in Chlamydia, containing a glycosoaminoglycan, especially heparin, in an amount sufficient to enhance assay sensitivity.
• the buffer contains at least about 0.1 mg/ml heparin. Normally it does not need to contain more than about 10 mg/ml heparin.
• Another embodiment of the invention is a method of preparing an aqueous assay sample from clinical material suspected of containing micro-organisms, such as Chlamydia, which express lipopolysaccharide antigen, wherein the clinical material or an aqueous extract thereof is contacted with an anionic polysaccharide, especially a glycosoaminoglycan such as heparin, in insolubilized form.
• an anionic polysaccharide especially a glycosoaminoglycan such as heparin
• the invention provides a procedure for extracting solubilized antigenic material from cellular biological material, such as bacteria, wherein the cellular material is treated with an aqueous solution of a surface active agent, in the presence of an anionic polysaccharide.
• a surface active agent is zwitterionic. More preferably, the surface active agent is 3-(3-chlolamidopropyl)dimethylammonio-1-propanesulfonate (conveniently known as CHAPS) or 3-(3-chlolamidopropyl)dimethylammonio-2-hydroxyl-1-propanesulfonate (conveniently known as CHAPSO), or mixtures thereof.
• An especially effective extraction of lipopolysaccharide antigen from Chlamydia species such as Chlamydia trachomitis, C.psittaci and C.twar, is achieved if the extraction is performed using an aqueous solution of heparin and a zwitterionic surface active agent, especially CHAPS and/or CHAPSO.
• the extraction is conducted at elevated temperature, for example in excess of about 50° C., for a period of time sufficient to solubilize the antigenic material. More preferably, the extraction temperature is at least about 60° C. In general, the extraction temperature need not be greater than about 100° C., and is preferably not greater than about 90° C. Ideally, the extraction temperature is about 80° C.
• the stage of the extraction conducted at such elevated temperature should generally last for at least about 5 minutes.
• the quantity of surface active agent in the aqueous extraction medium is at least about 0.1% by weight.
• the quantity of surface active agent is not greater than about 2%, and more preferably not greater than about 1% by weight.
• the pH of the extraction medium should generally be in the range of about 7.5 to about 9.
• the heparin or other anionic polysaccharides can be used either in soluble or insoluble form as desired. Heparin is available commercially in either form. One option is to have the anionic polysaccharide as a soluble component in the extraction buffer or added as a soluble component at a later stage before commencement of the actual assay procedure. Presence as a component in an extraction buffer is probably the most convenient from the user's point of view. Alternatively, an aqueous sample/extract can be contacted with an insolubilized form of the anionic polysaccharide, for example, heparin bound to a solid surface such as resin beads.
• the insolubilized anionic polysaccharide can be removed from the aqueous composition before the actual assay is conducted. For example beads can be centrifuged or filtered out. A solid phase of greater bulk, for example a high surface area dipstick on which the heparin is bound can be separated from the aqueous composition by manual extraction or decantation of the liquid.
• a variety of alternative formats will suggest themselves readily to the skilled reader.
• the essential objective is that the aqueous composition containing the lipopolysaccharide antigens to be assayed is exposed to the anionic polysaccharide under circumstances which permit the anionic polysaccharide to bind with and in effect, remove from the system at least a proportion of any cationic components present which might interfere with the accuracy of the lipopolysaccharide antigen assay.
• the optimum amount and presentation of the anionic polysaccharide can be determined by simple experiment.
• a biological sample obtained from a patient suspected of carrying a Chlamydia infection is contacted with the extraction medium.
• Appropriate samples can take the form, for example, of genital, rectal or ocular swabs, or centrifugal pellets from liquids such as early morning urine. Extraction, for example at 80° C. for 10 minutes, is followed by a brief period, for example 5 minutes, during which the extraction medium is allowed to cool. Thereafter the extraction medium can be separated from solid matter, for example by removal of the swab and filtration of the solution to provide a sample liquid containing any extracted antigen ready for use in any suitable assay procedure.
• the subsequent assay can involve any conventional assay technique, such as radioimmunoassay or enzyme-linked immunoassay.
• the extracted sample is ideal for use in an immunochromatographic assay procedure such as described and claimed in EP-A-291194, especially using a nitrocellulose solid phase and an antibody reagent labelled with a direct particulate label such as coloured latex particles.
• the use of heparin together with CHAPS and/or CHAPSO enhances the sensitivity of a Chlamydia assay which involves anti-lipopolysaccharide antigen antibodies as specific binding reagents.
• Chlamydia trachomatis An extraction procedure for Chlamydia trachomatis can be performed as follows. This provides an extract suitable for use in an immunoassay.
• Disposable, flexible plastic "test tubes” each capable of holding a volume (eg. 5 ml) of liquid and of accommodating the end of a conventional sampling swab.
• Means for filtering the liquid contents of the tube at the end of the extraction procedure can take the form of a filter plug incorporated in a perforated stopper with which the tube can be closed and through which the liquid contents can be expelled.
• a pre-determined quantity for example 600 ⁇ l
• a genital swab from a patient suspected of carrying a Chlamydia infection is placed in the tube, and the tube and contents are then incubated in the heating block at a temperature of approximately 80° C. for 10 minutes.
• the tube is removed from the heating block and allowed to cool for 5 minutes.
• the swab is lifted out of the extraction buffer and, before the swab is removed completely from the tube, the sides of the tube are pressed in gently by hand to squeeze liquid from the swab. The swab can then be removed completely from the tube and discarded.
• a perforated stopper containing a filter plug is inserted in the top of the tube, and the liquid contents of the tube can be expelled therethrough to provide an essentially clear liquid sample containing any extracted Chlamydia lipopolysaccharide antigen for use in a subsequent assay.
• one or more assay reagents such as labelled antibodies, can be added to the contents of the tube before the filter/stopper is applied to the tube.
• the assay can be conducted using any established procedure. Preferably this is accomplished by means of a particle-labelled reagent becoming bound, in a sandwich or competition format assay in the presence of lipopolysaccharide antigen, to reveal the result in a small detection zone, e.g. narrow line, on a porous carrier material such as a nitrocellulose strip, as generally described in EP-A-291194.
• Chlamydia negative female endocervical swabs were washed in saline, washes from five swabs were then pooled. New swab (C) pools were made for each experiment.
• Protamine (a small protein molecule) was used to simulate clinical sample interference, at 0.001 mg/ml.
• Heparin resin (SIGMA H-5380, Lot No. 61 H 9570) was used as a method for removing clinical interferences. Slurries were made using 50% resin to 50% water. 250 ⁇ l of slurry was centrifuged at 13500 rpm for 5 minutes, the supernatant removed and 300 ⁇ l sample added. Slurry was then mixed end-over-end for 5 minutes. The mixture was centrifuged at 13500 rpm for 5 minutes. The supernatant was then assayed as detailed below.
• Extraction buffer (as in Example 1) with and without 1 mg/ml soluble heparin (SIGMA).
• Resin-treated swab pool and untreated swab pool were added to extraction buffer in the presence of a known amount of Chlamydia antigen.
• Swab pool was then added to extraction buffer with and without dissolved heparin, in the presence of a known amount of Chlamydia antigen.
• Resin-treated swab pool and untreated swab pool were then added to extraction buffer (no heparin) with a known amount of Chlamydia antigen.
• the untreated swab pool was also tested using extraction buffer with dissolved heparin.
• 0.001 mg/ml protamine was used to simulate clinical sample interferences. Soluble heparin and insoluble heparin beads were used.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Biotechnology (AREA)
• Food Science & Technology (AREA)
• Virology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Microbiology (AREA)
• General Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=8221332

Family Applications (1)

Country Status (5)

Cited By (11)

Citations (8)

• 1996
  • 1996-08-12 AT AT96305901T patent/ATE190725T1/de not_active IP Right Cessation
  • 1996-08-12 ES ES96305901T patent/ES2145388T3/es not_active Expired - Lifetime
  • 1996-08-12 DE DE69607095T patent/DE69607095T2/de not_active Expired - Lifetime
  • 1996-09-04 JP JP23445196A patent/JP3534952B2/ja not_active Expired - Fee Related
  • 1996-09-13 US US08/713,849 patent/US6159703A/en not_active Expired - Lifetime

Patent Citations (11)

Non-Patent Citations (10)

Also Published As

Similar Documents

Legal Events